Search for Topics:
Title/Keyword
Journal
Submission Status
Category
 
 
Topics
New Metal-Based Drugs for Cancer Treatment: Single Molecules, Nanomaterials, and...
Propose a Topic

Topic Menu

► Topic Menu

Topic Editors

Escuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Blvd. Zertuche y Blvd., De los Lagos S/N Fracc, Valle Dorado, Ensenada 22890, Baja California, Mexico
Escuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Blvd. Zertuche y Blvd., De los Lagos S/N Fracc, Valle Dorado, Ensenada 22890, Baja California, Mexico
Dr. Gener José Avilés Rodríguez
Escuela de Ciencias de la Salud, Universidad Autónoma de Baja California, Ensenada, Mexico
Dr. Rodrigo Galindo-Murillo
Department of Medicinal Chemistry, IONIS Pharmaceuticals, Carlsbad, CA, USA
share announcement

New Metal-Based Drugs for Cancer Treatment: Single Molecules, Nanomaterials, and Beyond

Abstract submission deadline
closed (30 July 2023)
Manuscript submission deadline
closed (30 September 2023)
Viewed by
1951

Topic Information

Dear Colleagues,

The search for new therapeutic alternatives to combat cancer has found in the transition elements a very abundant source of compounds and nanostructures with different geometric arrangements and reactivity that provide unique opportunities to interact with varying sites of recognition and exert mechanisms of action other than those drugs that are currently used to kill tumor cells. These features not only provide new tools independently but also could provide advantages enhancing concomitantly or sequentially the effect of known antineoplastic agents. In this Topic, the most recent findings regarding preclinical studies of metallodrugs, including but not limited to synthesis, characterization, simulation, computational modeling, and theoretical approach to new antiproliferative and antitumor agents, qualitative/quantitative structure-activity studies, bio-speciation/bioaccumulation, interaction with specific enzymes and nucleic acids, cytotoxicity, genotoxicity, teratogenicity, and general toxicity will be outlined. Submissions of original papers and focused reviews are welcome.

Dr. Juan Carlos García-Ramos
Dr. Yanis Toledano-Magaña
Dr. Gener José Avilés Rodríguez
Dr. Rodrigo Galindo-Murillo
Topic Editors

Keywords

  • metalbased drugs
  • antiproliferative/antitumor activity
  • coordination compounds
  • organometallic compounds
  • metallic nanoparticles
  • apoptosis/necrosis
  • cytotoxic selectivity
  • genotoxicity
  • biodistribution
  • biospeciation/bioaccumulation
  • pharmacokinetics
  • simulation
  • computational chemistry
  • SAR/QSAR
  • molecular dynamics

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomedicines
biomedicines 		4.7 3.7 2013 14.7 Days CHF 2600
Cancers
cancers 		5.2 7.4 2009 18.2 Days CHF 2900
Future Pharmacology
futurepharmacol 		- - 2021 19.4 Days CHF 1000
Journal of Clinical Medicine
jcm 		3.9 5.4 2012 19.7 Days CHF 2600
Pharmaceutics
pharmaceutics 		5.4 6.9 2009 17 Days CHF 2900

Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.

Published Papers (1 paper)

Order results
Result details
Journals
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
21 pages, 4839 KiB  
Article
Heteroleptic Copper(II) Complexes Containing 2′-Hydroxy-4-(Dimethylamino)Chalcone Show Strong Antiproliferative Activity
by
Zdeněk Trávníček
,
Tomáš Malina
,
Ján Vančo
,
Marek Šebela
and
Zdeněk Dvořák
Pharmaceutics 2023, 15(2), 307; https://doi.org/10.3390/pharmaceutics15020307 - 17 Jan 2023
Cited by 1 | Viewed by 1198
Abstract
A series of six heteroleptic copper(II) complexes with 2′-hydroxy-4-(dimethylamino)chalcone (HL) with the composition [Cu(N-N)(L)]NO3 (1–6), where N-N stands for dmbpy = 5,5′-dimethyl-2,2′-bipyridine (1), bphen = 4,7-diphenyl-1,10-phenanthroline (2), dbbpy = 4,4′-di-tert-butyl-2,2′-bipyridine (3 [...] Read more.
A series of six heteroleptic copper(II) complexes with 2′-hydroxy-4-(dimethylamino)chalcone (HL) with the composition [Cu(N-N)(L)]NO3 (1–6), where N-N stands for dmbpy = 5,5′-dimethyl-2,2′-bipyridine (1), bphen = 4,7-diphenyl-1,10-phenanthroline (2), dbbpy = 4,4′-di-tert-butyl-2,2′-bipyridine (3), nphen = 5-nitro-1,10-phenanthroline (4), bpy = 2,2′-bipyridine, (5), and dpa = 2,2′-dipyridylamine (6), was prepared and thoroughly characterized. The in vitro cytotoxicity screening on eight human cancer cell lines identified complex 2, containing the bulkiest N-donor ligands (bphen) as highly cytotoxic against cancer cells, with IC50 values ranking from 1.0 to 2.3 μM, with good selectivity and low toxicity against healthy human fetal lung fibroblasts MRC-5. The cell-based assays, involving the most effective complex 2 in A2780 cancer cells, revealed its strong pro-apoptotic effects based on the effective activation of caspases 3/7, ROS overproduction, and autophagy in the A2780 cells while not impeding the cell cycle and mitochondrial membrane functions. The cellular uptake studies in A2780 and 22Rv1 cells uncovered no intracellular transport of the cationic complex 2, supporting the hypothesis that the in vitro anticancer effects of complex 2 are based on the combined extrinsic activation of apoptosis and autophagy induction. Full article
(This article belongs to the Topic New Metal-Based Drugs for Cancer Treatment: Single Molecules, Nanomaterials, and Beyond)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop